Glancy Prongay & Murray LLP Announces Investigation on Behalf of Behalf of MiMedx Group, Inc. Investors

Glancy Prongay & Murray LLP (“GPM”) announces that it has commenced an investigation on behalf of MiMedx Group, Inc. (“MiMedx” or the “Company) (NASDAQ: MDXG) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the MiMedx Group, Inc. investigation page on our website at https://www.glancylaw.com/case/mimedx-group-inc

On June 7, 2018, MiMedx disclosed that their “previously issued consolidated financial statements relating to each of the fiscal years ended December 31, 2012, 2013, 2014, 2015, and 2016 and each of the interim periods ended March 31, June 30 and September 30, 2017 should be restated. As a result, all communications and financial information with respect to the fourth quarter of 2017 and the first quarter of 2018 should no longer be relied upon, and the Company is withdrawing all prior financial guidance issued for 2018.”

On this news, MiMedx’s share price fell significantly on June 7, 2018.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased MiMedx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180607005903/en/